retatrutide phase 2 study results trial type 2 diabetes 2024 There are many great research studies to Retatrutide Shows Promising Results in

Its likely the drug will increase accessibility, remove barriers and lead to a rising number of patients using GLP-1s to lose and manage their weight

For glycaemic control in people with type 2 diabetes, doses of liraglutide above 1.8 mg once daily do not have a substantially greater effect

UK SmPCs advise that GLP-1 receptor agonists should be used with caution in patients with a history of pancreatitis

These hormones, known collectively as incretins, are secreted by the gut in response to nutrient ingestion and play crucial roles in metabolic regulation

A few things to note about this study is that there was no significant increase in risk for people after three years on these medications